Evidence map›Paper›PMID 28130263›Full record

ArticleAmerican journal of physiology. Lung cellular and molecular physiology2017

Magnetic resonance imaging of disease progression and resolution in a transgenic mouse model of pulmonary fibrosis.

Zackary I Cleveland, Yu M Zhou, Teckla G Akinyi, R Scott Dunn, Cynthia R Davidson, Jinbang Guo, Jason C Woods, William D Hardie

Open access · bronzeAbstract read
In one paragraph

Article in American journal of physiology. Lung cellular and molecular physiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Zackary I ClevelandCenter for Pulmonary Imaging Research, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; zackary.cleveland@cchmc.org.
Yu M ZhouCenter for Pulmonary Imaging Research, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Teckla G AkinyiCenter for Pulmonary Imaging Research, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
R Scott DunnImaging Research Center, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Cynthia R DavidsonDivision of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Jinbang GuoCenter for Pulmonary Imaging Research, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Jason C WoodsCenter for Pulmonary Imaging Research, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
William D HardieDivision of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Cincinnati Children's Hospital Medical Center · USUniversity of Cincinnati · USUniversity of Cincinnati Medical Center · USWashington University in St. Louis · US

Funding

LCenter for Clinical and Translational Science and TrainingUL1TR001425 · NCATS · UNIVERSITY OF CINCINNATI · PI HEUBI, JAMES E., KISSELA, BRETT M · 2015 to 2024
$37.5M
Molecular Interventions for pulmonary fibrosisP50HL107159 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI HARDIE, WILLIAM DAVID · 2011 to 2012
$932k
Ruth L. Kirschstein National Research Service Award Short-Term Institutional ReseT35HL113229 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI Raouf S. Amin, WILLIAM DAVID HARDIE · 2012 to 2026
$922k
Time-Resolved 129Xe Ventilation-Perfusion MRI in Models of Acute Lung InjuryR00HL111217 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI CLEVELAND, ZACKARY I · 2015 to 2017
$728k
NCATS NIH HHS UL1 TR001425NHLBI NIH HHS P50 HL107159NHLBI NIH HHS R00 HL111217NHLBI NIH HHS T35 HL113229
6 · The paper itself

Abstract

Pulmonary fibrosis contributes to morbidity and mortality in a range of diseases, and there are no approved therapies for reversing its progression. To understand the mechanisms underlying pulmonary fibrosis and assess potential therapies, mouse models are central to basic and translational research. Unfortunately, metrics commonly used to assess murine pulmonary fibrosis require animals to be grouped and euthanized, increasing experimental difficulty and cost. We examined the ability of magnetic resonance imaging (MRI) to noninvasively assess lung fibrosis progression and resolution in a doxycycline (Dox) regulatable, transgenic mouse model that overexpresses transforming growth factor-α (TGF-α) under control of a lung-epithelial-specific promoter. During 7 wk of Dox treatment, fibrotic lesions were readily observed as high-signal tissue. Mean weighted signal and percent signal volume were found to be the most robust MRI-derived measures of fibrosis, and these metrics correlated significantly with pleural thickness, histology scores, and hydroxyproline content (

Indexed as

Disease ProgressionAnimalsDisease Models, AnimalHydroxyprolineImaging, Three-DimensionalMagnetic Resonance ImagingMiceMice, TransgenicPulmonary FibrosisTransforming Growth Factor alphaHydroxyprolineTransforming Growth Factor alphainterstitial lung diseaseIPFmagnetic resonance imagingpulmonary fibrosisTGF-α

Identifiers

PMID28130263
PMCPMC5407091
OpenAlexW2581070713

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.